Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Artiva Biotherapeutics (NASDAQ:ARTV) from a sell rating to a hold rating in a research note published on Saturday morning.

A number of other equities research analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Wedbush raised their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. HC Wainwright lifted their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $11.22 on Friday. Artiva Biotherapeutics has a fifty-two week low of $2.22 and a fifty-two week high of $14.53. The company has a market capitalization of $277.36 million, a P/E ratio of -3.40 and a beta of 2.16. The stock has a 50-day simple moving average of $9.43 and a 200-day simple moving average of $7.81.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.63). As a group, analysts forecast that Artiva Biotherapeutics will post -2.45 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. acquired 24,944 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was bought at an average cost of $9.93 per share, with a total value of $247,693.92. Following the transaction, the director owned 17,329,570 shares of the company’s stock, valued at $172,082,630.10. The trade was a 0.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders purchased 1,965,251 shares of company stock worth $16,188,035 and sold 53,040 shares worth $477,890. 1.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Artiva Biotherapeutics

Large investors have recently modified their holdings of the stock. Prelude Capital Management LLC purchased a new position in Artiva Biotherapeutics in the 3rd quarter valued at $41,000. State of Wyoming purchased a new position in Artiva Biotherapeutics during the 2nd quarter worth $45,000. Bank of America Corp DE lifted its stake in shares of Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares during the period. Bridgeway Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth $53,000. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth $58,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.